Share Twitter LinkedIn Facebook Email Robert Rifkin, MD from Rocky Mountain Cancer Center discusses Carflizomib is extraordinarily active in myeloma and mainstay drug for physicians and patients at the 2017 American Society of Hematology.
Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD Acute Lymphoblastic Leukemia 4 Mins Read
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Acute Lymphoblastic Leukemia 3 Mins Read
FDA Approves Inotuzumab Ozogamicin (BESPONSA) for Acute Lymphoblastic Leukemia in Pediatric Patients [Exclusive Video] Acute Lymphoblastic Leukemia 3 Mins Read